Eli Lilly clears the one-trillion mark, shares near record territory on NYSE

By Thomas Klein, Operations & Strategy desk. Reviewed prior to publication on 2026-06-25, 18:59.

Eli Lilly & Co. (US5324571083) now trades on the NYSE with a market capitalization close to 1 trillion dollars, placing the pharmaceutical group among the most highly valued constituents of the S&P 500. Its shares recently changed hands around 1,135 dollars, only a few percentage points below their 52-week high from early June according to Financial Times data.

What the latest numbers show

Recent figures compiled by StockAnalysis put Eli Lilly’s market capitalization at roughly 996 billion dollars on the basis of a share price around 1,117 dollars, with trailing twelve-month revenue of about 72.3 billion dollars and net income near 25.3 billion dollars. This translates into earnings per share of approximately 28.15 dollars and a trailing price-earnings ratio close to 40, a level that clearly prices in strong growth expectations relative to many traditional large-cap pharmaceutical peers such as Novo Nordisk or Merck.

The same overview reports a forward price-earnings multiple just under 30, implying that analysts collectively expect robust earnings expansion over the coming periods. In addition, the stock offers a dividend of 6.92 dollars per share on a trailing basis, corresponding to a yield of around 0.6 percent at current price levels, which is modest compared with high-dividend healthcare names but typical for a growth-focused drug specialist.

Analyst opinions and consensus

Consensus data aggregated by StockAnalysis show that most analysts covering Eli Lilly rate the shares as a Buy, with an average price target of about 1,219 dollars per share, indicating expected upside of roughly 9 percent versus the latest quotation. According to this compilation, the stock’s 52-week trading range spans from around 624 dollars at the low to approximately 1,183 dollars at the high, highlighting the marked re-rating over the past year as the company’s new medicines gained traction.

Market commentary from the Financial Times notes that the shares recently traded near 1,135 dollars, around 4 percent below the 52-week high of 1,182.73 dollars set on 8 June 2026, keeping the stock within striking distance of its record level while remaining firmly entrenched among the largest companies on the NYSE by market value. Against this backdrop, Eli Lilly continues to feature prominently in discussions of high-growth healthcare leaders alongside peers such as Johnson & Johnson and Pfizer.

The medicines behind the valuation

Eli Lilly generates the bulk of its sales from innovative prescription medicines, with a current growth focus on diabetes and obesity therapies such as Mounjaro and Zepbound, as well as treatments in oncology and immunology. These products, built on the company’s long-standing expertise in metabolic and endocrine disorders, have driven the recent acceleration in revenue and profit that underpins the elevated valuation relative to traditional pharmaceutical benchmarks.

Where the shares trade today

The Eli Lilly shares (US5324571083) recently traded on the NYSE at about 1,135 dollars, as indicated by Financial Times market data for the latest session. At this level the stock’s market capitalization stands just under 1 trillion dollars, keeping the group firmly entrenched among the largest components of the S&P 500.

This article is for informational purposes only and does not constitute investment advice, a recommendation to buy or sell any financial instrument, or any other form of financial service. Historical performance is not a reliable indicator of future results.